Experimental Hematology
Volume 36, Issue 11 , Pages 1471-1479, November 2008

Genetic profiling of myeloproliferative disorders by single-nucleotide polymorphism oligonucleotide microarray

  • Norihiko Kawamata

      Affiliations

    • Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, Calif., USA
    • Corresponding Author InformationOffprint requests to: Norihiko Kawamata, M.D., Hematology/Oncology, Cedars-Sinai Medical Center, UCLA School of Medicine, 8700 Beverly Boulevard, Los Angeles, CA 90048
    • Drs. Kawamata and Ogawa contributed equally contributed to this work as the first authors.
  • ,
  • Seishi Ogawa

      Affiliations

    • Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan
    • Drs. Kawamata and Ogawa contributed equally contributed to this work as the first authors.
  • ,
  • Go Yamamoto

      Affiliations

    • Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan
  • ,
  • Soren Lehmann

      Affiliations

    • Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, Calif., USA
  • ,
  • Ross L. Levine

      Affiliations

    • Hematology, Brigham and Women's Hospital, Harvard University, School of Medicine, Boston, Mass., USA
  • ,
  • Yana Pikman

      Affiliations

    • Hematology, Brigham and Women's Hospital, Harvard University, School of Medicine, Boston, Mass., USA
  • ,
  • Yasuhito Nannya

      Affiliations

    • Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan
  • ,
  • Masashi Sanada

      Affiliations

    • Regeneration Medicine of Hematopoiesis, University of Tokyo, School of Medicine, Tokyo, Japan
  • ,
  • Carl W. Miller

      Affiliations

    • Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, Calif., USA
  • ,
  • D. Gary Gilliland

      Affiliations

    • Hematology, Brigham and Women's Hospital, Harvard University, School of Medicine, Boston, Mass., USA
  • ,
  • H. Phillip Koeffler

      Affiliations

    • Hematology/Oncology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, Calif., USA

Received 10 January 2008; received in revised form 11 June 2008; accepted 17 June 2008. published online 26 August 2008.

Objective

Myeloproliferative disorders (MPD) are clonal hematopoietic diseases that include polycythemia vera (PV), essential thrombocytosis (ET), and primary myelofibrosis (PMF). Mutations in JAK2 are present in many MPD patients. Additional genomic abnormalities are not fully examined in MPD.

Materials and Methods

We used single-nucleotide polymorphism DNA microarray (SNP-chip) to analyze 43 patients with MPD (10 PV, 17 ET, and 16 PMF) for genomic aberrations.

Results

Genomic abnormalities were rare in ET. The region containing either RB (13q14) or NF1 (17q11) was deleted in 4 of the 16 PMF, especially PMF with no JAK2 mutations. All five cases of PV having homozygous JAK2V617F had loss of heterozygosity with normal copy number [uniparental disomy] involving the gene. A subpopulation with 9p uniparental disomy was detected in 11 MPD (3 PV, 1 ET, 7 PMF). Uniparental disomy at 1p was found in one PV and three PMF. A novel mutation of MPL (Y591D), which was involved in this uniparental disomy, was found in 1 PV with JAK2 mutation. The other three cases of PMF with 1p uniparental disomy had point mutations of the MPL gene, either a novel mutation (S204F) or the previously described W515L.

Conclusion

Genomic abnormalities, including 9p uniparental disomy/JAK2 point mutations, 1p uniparental disomy/MPL point mutations, deletions of RB1 and NF1 are common alterations in MPD, especially in PMF.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-472X(08)00303-2

doi:10.1016/j.exphem.2008.06.006

Experimental Hematology
Volume 36, Issue 11 , Pages 1471-1479, November 2008